Sunday, October 25, 2020 10:36:13 AM
Yes..122million shares @$.001. It's called predatory venture capital lending. And whether or not it's worth diluting shareholder value by 1/3 as these shares hit the market...will depend on the results of their research and what they do with this $2Million to advance it QUICKLY!
If they can secure a patent for a COVID drug worth $billions...then shareholders would benefit regardless of the dilution
As far as alternatives they could have taken...that's another story. Not sure if all avenues were exhausted before this funding route was taken. That's the job of a CFO and if we didn't seriously look at selling the company's IP first and what the return would be under that scenario..then the CFO didn't do his job. OR maybe Dr. Steve doesn't want to sell now because he wants the personal glory of the discovery down the road...After all he's already a billionaire (he sold a company for $1BN before)
As an investor, I would have preferred an asset sale now for $1-$2 per share and be done with it. We now know that this technology is likely to be successful (UGA tells us that)...so they should have looked at selling it and the patent pending with it as an alternative.
If they can secure a patent for a COVID drug worth $billions...then shareholders would benefit regardless of the dilution
As far as alternatives they could have taken...that's another story. Not sure if all avenues were exhausted before this funding route was taken. That's the job of a CFO and if we didn't seriously look at selling the company's IP first and what the return would be under that scenario..then the CFO didn't do his job. OR maybe Dr. Steve doesn't want to sell now because he wants the personal glory of the discovery down the road...After all he's already a billionaire (he sold a company for $1BN before)
As an investor, I would have preferred an asset sale now for $1-$2 per share and be done with it. We now know that this technology is likely to be successful (UGA tells us that)...so they should have looked at selling it and the patent pending with it as an alternative.
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
